Replies to post #1335 on China BioPharma Corp (fka CHBO)

[DonLeopoldo]

Here is the chart, corrected.


Look at what happened with PLRS, last year, after the CD conversions were terminated;... the stock went very fast all the way up to more than a x2 of the Warrants conversion Price, which in CBPC is at 0.30-0.40.
So, considering a similar pattern, in CBPC, we should see a fast climb to above $0.60-$0.80.




"What do the letters mean on the left hand side of the "Time & Sales" column?

The "Time & Sales" column of the Quotemodule tool displays the "Trade Indicator" code on the left side of the column. A normal trade will have no Trade Indicators. "

Here are the original code descriptions:
a = acquisition
b = bunched trade - average price
c = cash trade
d = distribution
e = automatic execution
g = bunched sold trade - opening/reopening trade detail
h = intraday trade detail
i = basket index on close transaction
j = rule 127 trade
k = rule 155 trade
l = sold last
n= next day
o = opened
p = prior reference price
r = seller
s = split trade
t = form t trade - pre/post market trade
u = extended hours trade - reported late or out of sequence
w = average price trade
y = yellow flagged regular trade
z = sold - out of sequence

[MakeMoneyMan]

Looking at the Ludlow report they state with 10-13 mil of sales and p/s of 3 and only 90 million shares outstanding, the target would be .30 to .40
Don, how do you come up with .75 if you project twice the shares and half the revenue.
It would seem that the target would be more like .07 to .10 in this situaton (with twice the shares and half the revenue).



PRINCETON, N.J., June 18 /PRNewswire-FirstCall/ -- Ludlow China upgrades China Biopharma, Inc. (OTC Bulletin Board: CBPC - News) from a C to B- rating based on a recent guidance for fiscal year 2007 issued by the company. On June 13, 2007, the company issued revenue guidance for fiscal year 2007 of between $10 million to $13 million, with projected positive net income. Based on a price to sales (P/S) ratio of just 3 times sales that would give CBPC a valuation of $30 to $39 million. With around 90 million shares outstanding, that would give CBPC a potential target of around $0.30 to $0.40 a share